[1] DCCT-Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med. 1998 Apr 1; 128(7):517–23.

[2] Schiel R, Müller U. GAD autoantibodies in a selection-free population of insulin-treated diabetic patients: indicator of a high prevalence of LADA? Diabetes Res Clin Pract. 49:33-40, 2000

[3] Lampasona V, Liberati D. Islet Autoantibodies. Curr Diab Rep. 2016; 16:53

[4] Vandewalle CL et al. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry. J Clin Endocrinol Metab. 1995; 80:846–51.

[5] Kawasaki E. ZnT8 and type 1 diabetes. Endocr J. 2012; 59:531–7